Skip to main content
SLXNW logo

SLXNW · Silexion Therapeutics Corp

Track SLXNW — free
$0.00 +0.00 (+0.00%) At close · Nov 19
Market Cap
$974,292
Shares
649,528
Volume · Nov 19 300 Avg daily vol (3M) 39.06K

Price & Indicators

 

Key stats

Close
$0.00
Thu 19 Nov
Open
$0.00
Thu 19 Nov
Average volume, 30 days
54K
shares a session
Short interest
63K
9.7% of shares · 1.0 days to cover
Day range
$0.00$0.00
Open $0.00 Close $0.00
Available closing range
$0.00$0.03
Close $0.00 86.3% under the high
Short volume, last session
100%
Latest filing
10-Q · Nov 12
Price history
Jul 2026 to Nov 2026

The closing range uses available history since Jul 28, 2026; less than a full year is stored.

Latest documents

2026
Nov 19
Current report 8-K
Nasdaq panel keeps listing with financing conditions and deadlines

A Nasdaq Hearings Panel granted Silexion continued listing, subject to conditions. The company must complete a $2.5 million private placement by December 4, 2026, and a public offering of at least $5 million by March 31, 2027.

Other events
4 source passages
On November 18, 2026, Silexion Therapeutics Corp. granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the conditions described below by December 4, 2026, complete its planned private placement financing for net proceeds of $2.5 million by March 31, 2027, complete a planned public offering of at least $5 million Open the document at this passage
Nov 16
Current report 8-K
SIL204 first patient dosed in pancreatic cancer trial

Silexion Therapeutics Corp dosed its first patient with SIL204 on September 30, 2026 in a Phase 2/3 pancreatic cancer trial at Tel Aviv Sourasky Medical Center. Cash and cash equivalents were $4.8 million.

Financial results
2 source passages
On July 29, 2026, Silexion initiated its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer (“LAPC”) at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), and on September 30, 2026, announced that the first patient worldwide had been dosed at TASMC. As of September 30, 2026, Silexion had cash and cash equivalents of $4.8 million, compared to $6.0 million as of December 31, 2025, and $2.2 million as of June 30, 2026. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
SIL204 trial doses first patient amid Nasdaq listing uncertainty

Silexion Therapeutics Corp dosed its first SIL204 Phase 2/3 patient in locally advanced pancreatic cancer, while awaiting a Nasdaq listing decision. The company reported an $8.8 million nine-month net loss and said cash would fund only several months.

Net loss $2.53M Diluted EPS $13.70 ▼ 98.0%
Read from the MD&A section
4 source passages
During the third quarter of 2026, we initiated and successfully dosed the first patient in our Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer subjects, at the Tel Aviv Sourasky Medical Center (Ichilov) in Tel Aviv, Israel. As of the date of the filing of this quarterly report, we have not yet received a decision from the Nasdaq hearings panel as to our request to remain listed on Nasdaq. Our net losses were $2.5 million and $8.8 million for the three-month and nine-month periods ended September 30, 2026, respectively, and $11.9 million for the year ended December 31, 2025. Based on our current business plan, we believe our current cash and cash equivalents, and anticipated cash flow from operations, will not be sufficient to meet our anticipated cash requirements for the next 12 months but rather only for several months, from the filing date of this quarterly report, under our current business plan. Open the document at this passage
Nov 12
Current report 8-K
Warrants adjusted after 1-for-24 reverse share split

Silexion Therapeutics Corp completed a 1-for-24 reverse share split effective after trading on November 10, 2026, leaving 21,495,833 authorized ordinary shares at $3.24 par value and adjusting warrants to 1/24 share each at $372,600.00 per share.

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events
5 source passages
In connection with its previously-announced 1-for-24 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares (the “Reverse Share Split”) described in Item 5.03 below, on November 11, 2026, Silexion Therapeutics Corp (the “Company”) issued a notice (the “Warrant Adjustment Notice”) to holders of its public warrants and private warrants to purchase the Company’s ordinary shares (the “Warrants”). The Reverse Share Split became effective after the close of business on November 10, 2026, and the Company’s ordinary shares began trading on a Reverse Share Split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol “SLXN” at the market open on November 11, 2026. As a result of that filing, the authorized share capital of the Company remains at $69,646,500, now consisting of 21,495,833 ordinary shares, and the par value of the ordinary shares has increased from $0.135 per share to $3.24 per share. the number of ordinary shares issuable upon exercise of each pre-Reverse Share Split Warrant to purchase one ordinary share decreased proportionately to the Reverse Share Split ratio, resulting in each such Warrant being exercisable for 1/24th of an ordinary share following the Reverse Share Split; and the exercise price of each post-Reverse Share Split Warrant to purchase one whole post-Reverse Share Split ordinary share was proportionately increased 24-fold (relative to a pre-Reverse Share Split Warrant to purchase one pre-Reverse Share Split ordinary share), to $372,600.00 per post-Reverse Share Split ordinary share. Open the document at this passage
Nov 9
Current report 8-K
1-for-24 reverse split begins trading November 11, 2026

Silexion Therapeutics Corp will conduct a 1-for-24 reverse share split after market close on November 10, 2026, with split-adjusted Nasdaq Capital Market trading beginning November 11, 2026 under ticker “SLXN”; par value will rise from $0.135 per share to $3.24 per share.

Other events
3 source passages
Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-24 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 10, 2026, and the Company’s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at market open on November 11, 2026, under the existing ticker symbol “SLXN.” The par value of the ordinary shares will be proportionately increased, from $0.135 per share to $3.24 per share, and no fractional shares will be issued. Open the document at this passage
All documents

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+11% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.73% of shares out · ▼ -23.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — mid 2-yr range
Price context
position in its available closing range
Range low $0 Now $0 · 0% Range high $0
vs 50-day avg -57%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
gross proceeds $1.9M third quarter —
ordinary shares sold under ATM program, net of sales agent fees and issuance costs $1.8M the third quarter of 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SLXNW
Silexion Therapeutics Corp
this stock
$974,292 — — — —
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
31
% held
507.5%
Net QoQ
+874.7K sh
Top holder
BANK OF MONTREAL /CAN/
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
63.2K
Days to cover
1.0d
Change
-19.5K sh
View
Short Volume
Short vol %
100%
As of
Nov 10, 2026
Short Total
View
Fails to Deliver
FTD shares
962
Value
$164
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
31.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-11.9M
EPS diluted
$2150.40
View
Buybacks
Authorized
shares 59.5K
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 19, 2026
This year
59

A Nasdaq Hearings Panel granted Silexion continued listing, subject to conditions. The company must complete a $2.5 million private placement by December 4, 2026, and a public offering of at least $5 million by March 31, 2027.

View
Exempt Offerings
Offering
$3.6M
Filed
Aug 11, 2025
View
Earnings & Events
Investor Relations
Latest news
Silexion Therapeutics Reports Thi…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
SLXNW -4.7% -30.5% — -43.8% —
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +0.8% -24.2% — -38.6% —

Capital returns

Buyback program · as of Jul 4, 2024
Authorized
shares 59,525
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 2022416 CUSIP G1281K148 13F (30d) 27 filings 21 filers Visit website Investor relations